Good afternoon :)
Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd

ONESOURCE Share Price

NSE
₹1,569.600.42% (+6.60)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP

With a market cap of ₹17,923 cr, stock is ranked 383

Stock is 3.25x as volatile as Nifty

ONESOURCE Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

Avg

Average profitability - not good, not bad

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹17,923 cr, stock is ranked 383

Stock is 3.25x as volatile as Nifty

ONESOURCE Performance & Key Metrics

ONESOURCE Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
-10,996.063.07—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
45.815.760.50%

ONESOURCE Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 4 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

ONESOURCE Company Profile

OneSource Specialty Pharma Ltd is a contract development and manufacturing organization specializing in complex biologics, biosimilars, and vaccines.

Investor Presentation

View older View older 

Sep 3, 2026

PDF
View Older Presentations

ONESOURCE Similar Stocks (Peers)

Compare with peers Compare with peers 

ONESOURCE Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
148.41
148.41
1Y Return
6.59%
6.59%
Buy Reco %
69.23
69.23
PE Ratio
78.92
78.92
1Y Return
15.54%
15.54%
Buy Reco %
100.00
100.00
PE Ratio
94.85
94.85
1Y Return
69.23%
69.23%
Buy Reco %
87.50
87.50
PE Ratio
92.01
92.01
1Y Return
135.02%
135.02%
Buy Reco %
87.50
87.50
PE Ratio
72.88
72.88
1Y Return
13.54%
13.54%
Buy Reco %
100.00
100.00
Compare with Peers

ONESOURCE Sentiment Analysis

ONESOURCE Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

ONESOURCE Stock Summary · July 2026

Management struck a broadly upbeat tone, saying the quarter combined strong execution with rising commercial momentum across its platform. Revenue grew 37% year on year to INR 4,490 million and EBITDA increased 39% to INR 1,233 million, supported by the semaglutide launch, new MSA contracts and customer wins. A major focus was the acceleration of semaglutide commercialization, with all three market approvals now in place, partner launches underway in Canada and India, and more than 40% of the generic pens market in India already being manufactured at the company’s site by late June. Management also emphasized that capacity expansion is removing prior bottlenecks: the second cartridge line is on track this quarter, should double sterile production days, and is expected to support resumed supply to Dr. Reddy’s and new customer onboarding later in the year. Alongside this, the company described growing opportunity in softgels, injectables and biologics, while noting some near-term disruption from freight and shipping pressures. Management reiterated its FY28 target of $400 million of organic revenue and 40% EBITDA margins, saying it has sufficient visibility to support that outlook.

ONESOURCE Stock Growth Drivers
ONESOURCE Stock Growth Drivers
10
  • Strong Revenue and EBITDA Growth

    The company delivered a strong quarter, with revenue rising 37% year on year to INR

  • Semaglutide Commercialization Gains

    Commercialization of semaglutide is accelerating across key markets, with meaningful traction already visible in Canada

ONESOURCE Stock Challenges
ONESOURCE Stock Challenges
4
  • Capacity Constraints and Delayed Revenue Capture

    The company is still operating under meaningful capacity constraints, with prior demand exceeding available sterile

  • Limited Near-Term Impact From Oncology Soft-Gel Launch

    The first oncology soft-gel NDA is an important strategic milestone, but the commercial upside is

ONESOURCE Forecast

ONESOURCE Forecasts

Price

Revenue

Earnings

ONESOURCE

ONESOURCE

Income

Balance Sheet

Cash Flow

ONESOURCE Income Statement

ONESOURCE Income Statement

Loading...

Quarterjun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026sep 2026
Total Revenue296.28338.45399.28428.84332.54378.80294.97430.34452.83517.20
Operating & Other expensessubtract232.51262.58351.20244.13241.66269.27280.11336.30329.98354.72
Depreciation/Amortizationsubtract68.3568.2868.7768.4967.8069.8369.6471.8371.7575.05
Interest & Other Itemssubtract42.0545.0545.8233.4127.4833.9638.2322.5130.8134.56
Taxes & Other Itemssubtract-41.074.632.35-15.69-4.21-4.74-4.31-4.89-4.70-4.62
EPS-0.51-10.13-6.318.61-0.020.92-7.740.402.185.01

ONESOURCE Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2027FY 2027

Annual Report Pending

Investor Presentation

Sep 3PDF
FY 2026FY 2026

Annual report

PDF

Investor Presentation

May 13PDF
Jan 23PDF
Nov 12PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 6PDF
 

ONESOURCE Stock Peers

ONESOURCE Past Performance & Peer Comparison

ONESOURCE Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareBiotechnology

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Onesource Specialty Pharma Ltd-242.833.07—
Biocon Limited148.411.560.14%
Anthem Biosciences Limited78.9215.350.24%
Sai Life Sciences Limited94.8513.32—
ScreenerCompare valuation on Screener

ONESOURCE Stock Price Comparison

Compare ONESOURCE with any stock or ETF
Compare ONESOURCE with any stock or ETF
ONESOURCE
Loading...

ONESOURCE Holdings

ONESOURCE Shareholdings

ONESOURCE Promoter Holdings Trend

ONESOURCE Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

ONESOURCE Institutional Holdings Trend

ONESOURCE Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

ONESOURCE Shareholding Pattern

ONESOURCE Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding30.47%13.76%10.45%19.46%25.87%

Dec 2025

Mar 2026

Jun 2026

Sep 2026

ONESOURCE Shareholding History

ONESOURCE Shareholding History

JunSepDec '25MarJunSep18.69%19.39%19.24%17.50%19.19%19.46%

Mutual Funds Invested in ONESOURCE

Mutual Funds Invested in ONESOURCE

No mutual funds holding trends are available

Top 5 Mutual Funds holding Onesource Specialty Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
3.1596%2.86%-0.65%15/37 (0)
2.0300%2.71%-0.16%16/36 (+1)
0.9253%3.39%-0.75%13/37 (-8)

Compare 3-month MF holding change on Screener

ONESOURCE Insider Trades & Bulk Stock Deals

ONESOURCE Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing ONESOURCE stock

smallcases containing ONESOURCE stock

Looks like this stock is not in any smallcase yet.

ONESOURCE Events

ONESOURCE Events

ONESOURCE Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

ONESOURCE has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

ONESOURCE Dividend Trend

No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

ONESOURCE has not given any dividends in last 5 years

ONESOURCE Dividends

ONESOURCE Dividends

Hmm, looks like data is unavailable here. Please come back after some time

ONESOURCE Stock News & Opinions

ONESOURCE Stock News & Opinions

Earnings
Earnings
OneSource Specialty Pharma Ltd consolidated sales up 14.97% on year in Q3FY2026, net profit saw a strong growth of 129.92%

OneSource Specialty Pharma Ltd share price rallied 13.96% to Rs 1591.25 after the company's net profit soared by 129.92% to Rs 57.48 crore, while revenue from operations gained 14.97% to Rs 516.24 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.44 lakh crore, rising 4.06%. It has marginally improved by 3.17% over last one week and edged lower by 0.26% in last one month while the market capitalization of OneSource Specialty Pharma Ltd has sharply increased by 17.77% and 5.50% in the same period respectively. Profit before tax (PBT) of OneSource Specialty Pharma Ltd stood at Rs 52.87 crore in Q3 FY26, jumping 821.08% year-on-year, and rallying 160.57% quarter-on-quarter. EBITDA came in at Rs 162 crore, surging by 56.91% YoY and expanding by 35.79% sequentially. Total expenses saw a slight increase of 7.69% to Rs 428.0 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 152.25 crore, growing marginally by 7.83% YoY, while employee benefits expense was at Rs 77.58 crore, witnessing a strong rise of 12.96% YoY. For the TTM ended FY26, revenue from operations softened by 1.61% to Rs 1421.59 crore, while net profit surged by 327.08% to Rs 73.8 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 45325% to Rs 289.2 crore, and PBT soared 37.11% to Rs 91.96 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 8.52 crore in FY26, as against Rs 67.85 crore in FY25. OneSource Specialty Pharma Ltd crashed 11.98% in last one year, outperforming the benchmark BSE Sensex which has reduced by 13.19% during the same period.

5 days agoCapital Market - Live
Spotlight
Spotlight
Volumes jump at OneSource Specialty Pharma Ltd counter

Sona BLW Precision Forgings Ltd, Acutaas Chemicals Ltd, Dalmia Bharat Ltd, Ola Electric Mobility Ltd are among the other stocks to see a surge in volumes on NSE today, 27 October 2026.OneSource Specialty Pharma Ltd witnessed volume of 63.3 lakh shares by 14:24 IST on NSE, a 37.65 times surge over two-week average daily volume of 1.68 lakh shares. The stock increased 13.79% to Rs.1,590.00. Volumes stood at 2.28 lakh shares in the last session.Sona BLW Precision Forgings Ltd registered volume of 173.84 lakh shares by 14:24 IST on NSE, a 8.45 fold spurt over two-week average daily volume of 20.57 lakh shares. The stock rose 8.07% to Rs.845.00. Volumes stood at 30.96 lakh shares in the last session.Acutaas Chemicals Ltd recorded volume of 39.9 lakh shares by 14:24 IST on NSE, a 8.39 times surge over two-week average daily volume of 4.76 lakh shares. The stock gained 15.86% to Rs.3,880.00. Volumes stood at 12.45 lakh shares in the last session.Dalmia Bharat Ltd saw volume of 5.83 lakh shares by 14:24 IST on NSE, a 7.64 fold spurt over two-week average daily volume of 76305 shares. The stock dropped 7.31% to Rs.1,506.90. Volumes stood at 54656 shares in the last session.Ola Electric Mobility Ltd registered volume of 2419.11 lakh shares by 14:24 IST on NSE, a 6.78 fold spurt over two-week average daily volume of 356.63 lakh shares. The stock rose 11.89% to Rs.33.50. Volumes stood at 436.09 lakh shares in the last session.

5 days agoCapital Market - Live
Earnings
Earnings
OneSource Specialty Pharma Ltd consolidated sales up 14.97% on year in Q3FY2026, net profit saw a strong growth of 129.92%

OneSource Specialty Pharma Ltd share price inched up 4.77% to Rs 1396.3 after the company's net profit jumped 129.92% to Rs 57.48 crore, while revenue from operations increased 14.97% to Rs 516.24 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.54 lakh crore, rising 3.42%. It has marginally improved by 0.07% over last one week and softened by 3.01% in last one month while the market capitalization of OneSource Specialty Pharma Ltd has improved by 1.22% and 20.12% in the same period respectively. Profit before tax (PBT) of OneSource Specialty Pharma Ltd stood at Rs 52.87 crore in Q3 FY26, expanding by 821.08% year-on-year, and rallying 160.57% quarter-on-quarter. EBITDA came in at Rs 162 crore, jumping 56.91% YoY and surging by 35.79% sequentially. Total expenses grew marginally by 7.69% to Rs 428.0 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 152.25 crore, posting a minor increase of 7.83% YoY, while employee benefits expense was at Rs 77.58 crore, witnessing a strong rise of 12.96% YoY. For the TTM ended FY26, revenue from operations declined slightly by 1.61% to Rs 1421.59 crore, while net profit surged by 327.08% to Rs 73.8 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 45325% to Rs 289.2 crore, and PBT soared 37.11% to Rs 91.96 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 8.52 crore in FY26, as against Rs 67.85 crore in FY25. OneSource Specialty Pharma Ltd plunged by 22.77% in last one year, underperforming the benchmark BSE Sensex which has slipped by 13.18% during the same period.

6 days agoCapital Market - Live
Spotlight
Spotlight
OneSource Specialty Pharma Ltd leads gainers in 'A' group

India Glycols Ltd, Ola Electric Mobility Ltd, Zaggle Prepaid Ocean Services Ltd and Sona BLW Precision Forgings Ltd are among the other gainers in the BSE's 'A' group today, 27 October 2026.OneSource Specialty Pharma Ltd spiked 12.08% to Rs 1565 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 75450 shares were traded on the counter so far as against the average daily volumes of 31599 shares in the past one month. India Glycols Ltd soared 11.93% to Rs 320.3. The stock was the second biggest gainer in 'A' group. On the BSE, 46350 shares were traded on the counter so far as against the average daily volumes of 1.6 lakh shares in the past one month. Ola Electric Mobility Ltd surged 10.89% to Rs 33.19. The stock was the third biggest gainer in 'A' group. On the BSE, 88.99 lakh shares were traded on the counter so far as against the average daily volumes of 41.7 lakh shares in the past one month. Zaggle Prepaid Ocean Services Ltd advanced 10.74% to Rs 167.55. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.73 lakh shares were traded on the counter so far as against the average daily volumes of 54853 shares in the past one month. Sona BLW Precision Forgings Ltd gained 8.92% to Rs 853.85. The stock was the fifth biggest gainer in 'A' group. On the BSE, 6.57 lakh shares were traded on the counter so far as against the average daily volumes of 3.16 lakh shares in the past one month.

6 days agoCapital Market - Live
Corporate
Corporate
OneSource Specialty Pharma changes Dr. Albrecht’s director designation, effective October 2026

OneSource Specialty Pharma Limited announced that the board of directors approved a change in designation for Dr. Claudio Albrecht, shifting his role from Independent Director to Non-Executive Non-Independent Director, effective October 27, 2026, subject to shareholder approval. Dr. Albrecht is Co-Founder and Managing Partner of Albrecht, Prock & Partners AG and previously held leadership positions at Ratiopharm Group, Actavis Group, and STADA AG.

6 days agoCapital Market - Live
Corporate
Corporate
OneSource Specialty Pharma allotted equity shares to employees under its 2021 ESOP plan

OneSource Specialty Pharma Limited announced the allotment of 360 equity shares under its OneSource ESOP 2021 plan to eligible employees, according to a regulatory filing on October 27, 2026. The allotment increased the company's paid-up share capital from Rs 11,46,73,791 constituting 11,46,73,791 equity shares of Rs 1 each to Rs 11,46,74,151 constituting 11,46,74,151 equity shares of Rs 1 each. The exercise price per share was Rs 278, with a premium of Rs 277.

6 days agoCapital Market - Live
Corporate
Corporate
OneSource Specialty Pharma to review quarterly results at a board meeting on October 27

OneSource Specialty Pharma Limited will hold a board meeting on Tuesday, October 27, 2026, to consider and approve the unaudited financial results (standalone and consolidated) for the quarter ended September 30, 2026, according to a regulatory filing with the BSE Limited and National Stock Exchange of India Ltd. The trading window for designated persons of the company was closed from October 1, 2026, and will reopen 48 hours after the financial results are disseminated.

1 week agoCapital Market - Live
Corporate
Corporate
OneSource Specialty Pharma allotted equity shares under its ESOP plan, increasing share capital

OneSource Specialty Pharma Limited announced the allotment of 900 equity shares of Indian Rupees 1 each under its OneSource ESOP 2021 plan to an eligible employee, according to a circular resolution passed by the company’s Management Committee on September 25, 2026. The allotment increased the company's paid-up share capital from Indian Rupees 11,46,72,891 to Indian Rupees 11,46,73,791, comprising 11,46,73,791 equity shares.

1 month agoCapital Market - Live
Corporate
Corporate
OneSource Specialty Pharma closes share trading window ahead of quarterly results

OneSource Specialty Pharma Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in shares of the company will be closed from Thursday, October 01, 2026, until 48 hours after the declaration of financial results for the quarter ended September 30, 2026.

1 month agoCapital Market - Live
Corporate
Corporate
OneSource Specialty Pharma appoints B S R & Co LLP as auditors for five years

OneSource Specialty Pharma Limited announced that shareholders appointed M/s B S R & Co LLP, Chartered Accountants (Firm’s Registration No.:101248W/W-100022), as its statutory auditors for a period of 5 consecutive years, effective from the conclusion of the 19th Annual General meeting until the conclusion of the 24th Annual General Meeting, during a meeting held on Wednesday, September 23, 2026.

1 month agoCapital Market - Live

Frequently asked questions

  1. The share price of ONESOURCE as on 2nd November 2026 is ₹1569.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Onesource Specialty Pharma Ltd (ONESOURCE) share are
    • Past 1 week: 14.51%
    • Past 1 month: -1.69%
    • Past 3 months: -7.42%
    • Past 6 months: -10.07%
    • Past 1 year: -15.45%
    • Past 3 years: N/A%
    • Past 5 years: -8.60%

  3. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Onesource Specialty Pharma Ltd (ONESOURCE) is ₹17923.57 Cr as of 2nd November 2026.

  4. The 52-week high of Onesource Specialty Pharma Ltd (ONESOURCE) is ₹1925 and the 52-week low is ₹1057.

  5. The P/E (price-to-earnings) ratio of Onesource Specialty Pharma Ltd (ONESOURCE) is -242.83. The P/B (price-to-book) ratio is 3.07.

  6. Onesource Specialty Pharma Ltd (ONESOURCE) belongs to the Health Care sector & Biotechnology sub-sector.

  7. You can directly buy Onesource Specialty Pharma Ltd (ONESOURCE) shares on Tickertape. Simply sign up, connect your demat account and place your order.